NuVasive

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

Retrieved on: 
Wednesday, May 1, 2024
Optical, Health, Surgery, Medical Devices, Corporation, Science, Medtech, Near-sightedness, Law, University, Presbyopia, American Tower, Believer, EVO, General counsel, OTC, Marketing, Commerce, Johnson & Johnson, STAAR, Surgeon, University School, Business, Partner (business rank), CareFusion, Contact, Duke University, NuVasive, Senior, Patient, Multimedia, Global marketing, Emory University, Associate, Astigmatism, Economics, Nate, Growth, Engineering, Management

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.
  • View the full release here: https://www.businesswire.com/news/home/20240501408389/en/
    “We are thrilled to strengthen the STAAR team with the addition of Nancy and Nate, two seasoned executives with extensive senior leadership experience.
  • “Nancy is a perfect fit for the newly created Chief Marketing Officer position and will be critical to driving our brand awareness and innovation globally.
  • “I am thrilled to join the STAAR leadership team at a time of significant opportunity and growth for our vision correction lenses,” said Nate Sisitsky.

Theradaptive Strengthens Executive Team with Hire of Frank Vizesi as Chief Scientific Officer

Retrieved on: 
Tuesday, April 16, 2024
Safety, Surgeon, Paint, Trial of the century, Protein engineering, Therapy, NuVasive, Patient, Spinal fusion, Sports medicine, Ageing, Food and Drug Administration, Management

FREDERICK, Md., April 16, 2024 /PRNewswire/ -- Theradaptive, the market leader in targeted regenerative therapeutics, today announced the expansion of its senior leadership team with the appointment of Dr. Frank Vizesi, Ph.D. as Chief Scientific Officer.

Key Points: 
  • Frank brings over 20 years experience in cutting-edge orthobiologics research, with previous roles at NuVasive, SeaSpine and most recently as Chief Scientific Officer at Orthofix.
  • FREDERICK, Md., April 16, 2024 /PRNewswire/ -- Theradaptive , the market leader in targeted regenerative therapeutics, today announced the expansion of its senior leadership team with the appointment of Dr. Frank Vizesi, Ph.D. as Chief Scientific Officer.
  • Frank joins from Orthofix, where he was Chief Scientific Officer, and brings over two decades of experience in orthobiologics and spinal fusion.
  • "I have dedicated my career to developing the best solutions for spinal fusion, and I am delighted to be part of a team that is developing by far the most exciting innovation I have seen in the space," said Dr. Frank Vizesi, Chief Scientific Officer at Theradaptive.

Lucas Vitale Joins Orthofix as Chief People and Business Operations Officer

Retrieved on: 
Monday, March 18, 2024
Medical Devices, Health, Hospitals, Surgery, General Health, Biotechnology, Inclusion, NuVasive, Bruker, Equity, Therapy, CHRO, Spine, Multimedia, Business operations, Elective surgery, Management

(NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Lucas Vitale has joined the company in the newly created role of Chief People and Business Operations Officer.

Key Points: 
  • (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Lucas Vitale has joined the company in the newly created role of Chief People and Business Operations Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240318931186/en/
    Lucas Vitale, appointed Chief People and Business Operations Officer at Orthofix (Photo: Business Wire)
    Vitale most recently served as the Chief Human Resources Officer (CHRO) at ReNAgade Therapeutics, a venture backed pharmaceutical company, and prior to that, he served as the CHRO at Berkeley Lights/PhenomeX, a life sciences tools and services company acquired by Bruker.
  • “We are pleased to welcome Lucas to our executive leadership team,” said Massimo Calafiore, President and Chief Executive Officer of Orthofix.
  • “In this pivotal role, he will lead the company’s ongoing integration and business transformation strategies as we continue to strengthen our infrastructure to support future growth.”
    “I am excited by the continued opportunities to bring Orthofix and SeaSpine together,” said Lucas Vitale, Chief People and Business Operations Officer.

Globus Medical Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 20, 2024
Acquisition, Philosophy, Spine, Globus Medical, Telephone, ID, Surgeon, NuVasive, GAAP, Webcast, Patient, EPS, Globus, Pharmaceutical industry

AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023.
  • U.S. net sales for the fourth quarter of 2023 increased by 111.1% compared to the fourth quarter of 2022. International net sales increased by 200.9% over the fourth quarter of 2023 on an as-reported basis, and an increase of 200.8% on a constant currency basis.
  • Diluted EPS for the fourth quarter was $0.11, compared to $0.49 for the fourth quarter of 2022.
  • Globus Medical will hold a teleconference to discuss its 2023 fourth quarter and full year results with the investment community at 4:30 p.m. Eastern Time today.

J. Kurt Jacobus, Ph.D. Joins CurvaFix Board of Directors

Retrieved on: 
Tuesday, March 5, 2024
Medical Devices, Health, Surgery, Other Health, General Health, Biotechnology, Acquisition, Champaign–Urbana metropolitan area, Bone fracture, Enovis, Mechanical, Foot, Doctor of Philosophy, Pelvis, NuVasive, University, Mechanical engineering, Patient, Anatomy, Science, Trauma, Research, Nursing

CurvaFix, Inc ., a developer of medical devices that deliver stable fixation for curved anatomy and poor bone quality, announced today the appointment of J. Kurt Jacobus, Ph.D., as the newest member of its Board of Directors.

Key Points: 
  • CurvaFix, Inc ., a developer of medical devices that deliver stable fixation for curved anatomy and poor bone quality, announced today the appointment of J. Kurt Jacobus, Ph.D., as the newest member of its Board of Directors.
  • “We are delighted to welcome Kurt to CurvaFix’s Board of Directors,” said Mark Foster, CEO at CurvaFix.
  • “His extensive experience and proven track record of success in the orthopedic medical device sector makes him an invaluable addition to our board.
  • “I am honored to join CurvaFix’s excellent Board of Directors,” said Dr. Jacobus.

Spinal Non-Fusion Devices Market Poised for Growth: Global Insights and Forecast to 2030 - Escalating Prevalence of Spinal Disorders, Advanced Product Options, and Product Developments - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, General Health, Surgery, Medical Devices, Health, Spine, Incidence, Competitive landscape, USD, FDA, Ageing, Growth, World Health Organization, Projection, Prevalence, Tetraplegia, Medtronic, NuVasive, Accident, Research, Medical device

The "Spinal Non-Fusion Devices Market Insights, Competitive Landscape and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spinal Non-Fusion Devices Market Insights, Competitive Landscape and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • According to a detailed market assessment, the Spinal Non-Fusion Devices sector was valued at a commendable USD 2,757.17 million in the year 2023.
  • The expected growth trajectory is attributed to the escalating prevalence of spinal disorders, advanced product options, and burgeoning product development endeavors.
  • With specialized segmentation ranging from product type to global geography, this comprehensive market assessment elucidates the dynamic environment of the Spinal Non-Fusion Devices market.

Baxter Reports Fourth-Quarter and Full-Year 2023 Results

Retrieved on: 
Thursday, February 8, 2024
Medical Supplies, Health, Medical Devices, General Health, Pharmaceutical, Optical, Biotechnology, EPS, Task force, DNA, Nursing care plan, Piperacillin, Noise, Corporate social responsibility, FDA, Corporation, Medicine, UN, Dow Jones, EMR, Failure, Baxter International, Growth, Perioperative, TCFD, DJSI, Patient, Tazobactam, Centrella, Skin, Thrombin, Risk, Warburg Pincus, Acute liver failure, Galaxy, PD, NuVasive, Peritoneal dialysis, Risk management, Advent International, BPS, Sale, Eye, CST, Pharmaceutical industry

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.
  • For full-year 2023, net income attributable to Baxter on a U.S. GAAP basis totaled $2.66 billion, or $5.25 per diluted share.
  • In 2023, the company was named to the Dow Jones Sustainability Index (DJSI) North America, which has included Baxter each year since it launched in 2005.
  • For full-year 2024: Baxter expects sales growth of approximately 2% on both a reported and constant currency basis.

Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer

Retrieved on: 
Monday, February 5, 2024
NuVasive, Growth, Pfeil, Globus, CFO, Globus Medical, Management

AUDUBON, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the promotion of Keith Pfeil as chief operating officer (COO) and chief financial officer (CFO).

Key Points: 
  • AUDUBON, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the promotion of Keith Pfeil as chief operating officer (COO) and chief financial officer (CFO).
  • Having served as the Company’s CFO since August 2019, in this expanded role, Pfeil will help further drive the Company's strategic roadmap through business and operational planning as well as financial performance management.
  • "With a track record of over 20 years of high-performance industry experience, including the past four years with Globus, Keith has demonstrated operational and financial leadership and a deep passion for our business," said Dan Scavilla, president and chief executive officer of Globus Medical, to whom Pfeil will continue reporting.
  • The Company expects to announce its fourth quarter and full year 2023 financial results on February 20, 2024, after the market close.

Amanda Bloom Joins Spineology as Executive Vice President of Marketing

Retrieved on: 
Tuesday, January 16, 2024
Surgery, Medical Devices, Hospitals, Marketing, Communications, Health Technology, Practice Management, Biotechnology, Health, Patient, MIS, DePuy Synthes, Clinical, Spine, Software, Education, Medical device, Medtech, Product marketing, Ultra, Johnson & Johnson, Robotics, NuVasive, Organization, Surgeon, Inc., Growth, Management

Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Amanda Bloom as Executive Vice President, Marketing.

Key Points: 
  • Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Amanda Bloom as Executive Vice President, Marketing.
  • Bloom comes to Spineology with extensive experience, having served in the Medical Device and Technology fields related to spinal implants, procedures, robotics, software, navigation, and imaging.
  • “I am thrilled to have Amanda join the executive leadership team at Spineology after having had the privilege to work with her at NuVasive,” said Brian Snider, Chief Executive Officer.
  • Most recently, Bloom served as Vice President of Marketing for two innovative start-up organizations; Avail Medsystems, and Radiaction Medical, both providing novel solutions to unique, unmet clinical needs across multiple surgical disciplines.

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results

Retrieved on: 
Wednesday, January 10, 2024
Seed, Patient, Health, CFO, Spine, Enabling, Globus Medical, Globus, NuVasive

AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2023.

Key Points: 
  • AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2023.
  • The company anticipates fourth quarter 2023 sales of approximately $615.5 million, an increase of 124.2 percent over the fourth quarter 2022 on an as-reported basis.
  • “Excluding the impacts of the September 1, 2023 merger with NuVasive, Inc., legacy Globus fourth quarter revenue was approximately $302.9 million, an increase of 10.4 percent over the prior year fourth quarter.
  • The company expects to announce its fourth quarter and full year 2023 financial results on February 20, 2024, after the market close.